# AngioDynamics (ANGO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ANGO
## Company Profile
- Ticker: ANGO
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: MedTech, Oncology
## Stock Data
- Close: 15.75 USD
- Market cap: 453681686.7 USD
- Last updated: 2026-08-12
## Business Overview
### Vascular and Interventional Technology
AngioDynamics develops medical technologies that restore blood flow, remove thrombus and treat selected tumors. Its portfolio is organized around higher-growth interventional platforms and a broader medical-device business.
### Mechanical Thrombectomy
AlphaVac and AngioVac are mechanical aspiration systems used to remove thrombus or other material from the vascular system. The portfolio addresses complex venous and cardiac clot-management procedures.
### Auryon
Auryon is a peripheral atherectomy platform used to treat arterial disease by removing or modifying obstructive plaque. It supports limb-preservation and vascular-intervention procedures.
### NanoKnife
NanoKnife uses irreversible electroporation to ablate targeted soft tissue with electrical pulses. The platform is used in interventional oncology and is gaining support from a dedicated reimbursement code for prostate procedures.
## Why The Stock Is Moving

As of Aug 12, 2026, ANGO was little changed and closed at $15.75. No new same-company headline was identified in the current news window.

## Future Catalysts

- AngioDynamics’s catalysts are NanoKnife and Auryon adoption, plus broader vascular and oncology procedural growth. The stock improves when the company shows its device portfolio is gaining real clinical traction.

## Recent News
- 2026-07-28 12:30 EST — [AngioDynamics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ANGO/angiodynamics-to-participate-in-upcoming-investor-conferences-da9e7851) — Source: AngioDynamics
- 2026-07-14 10:00 EST — [AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability](https://biopharmsignal.com/news/ANGO/angiodynamics-reports-record-fiscal-year-2026-fourth-quarter-and-full-year-finan-44aa8657) — Source: AngioDynamics
- 2026-06-30 12:00 EST — [AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026](https://biopharmsignal.com/news/ANGO/angiodynamics-to-report-fiscal-2026-fourth-quarter-and-full-year-financial-resul-d0a55e66) — Source: AngioDynamics
- 2026-06-17 12:30 EST — [AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)](https://biopharmsignal.com/news/ANGO/angiodynamics-receives-fda-ide-approval-for-relief-feasibility-study-evaluating--d19f649d) — Source: AngioDynamics
- 2026-05-28 17:25 EST — [AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect](https://biopharmsignal.com/news/ANGO/angiodynamics-expands-patient-access-to-nanoknife-ire-for-prostate-and-liver-cancer-as-medicare-coverage-framework-takes-effect) — Source: AngioDynamics